Prashanth Jayaram, MD

Some VC investors believe that brick and mortar - referring to a physical presence of some kind - should be avoided at all costs. Yet, the track record of clinic and hybrid care businesses in health care indicates otherwise. ==> One Medical (sold for $3.9 billion to Amazon), Oak Street (bought by CVS for $10.6 billion), Lifestance (IPO at $7.5 billion market cap), and PE-backed Premise Health (acquired by OMERS Private Equity for $1.1 billion) If a clinic is indicated as the optimal way to deliver care for that patient population, there are creative ways to build and operate them. Full article below with advice and strategies on how to build and operate hybrid clinics from my teammate Anarghya Vardhana from Maveron, Amir Dan Rubin from OneMedical Group, Steven Eidelman from Modern Animal and more!

13

1 Comment

"Digital health is no longer the future; it is the present, reshaping our healthcare landscape in real-time." Excited to be part of the UCSF Digital Health Hub Foundation's Quarterfinalist Party! As a past board member, I'm honored to celebrate the outstanding quarterfinalists. As we reflect on the state of digital health in 2024, it's evident that the COVID-19 pandemic has fundamentally transformed healthcare delivery. The rapid adoption of telemedicine during the crisis has become a permanent fixture, with over 60% of physicians continuing to utilize this technology. The sprint towards smarter healthcare, catalyzed by necessity, has shattered preconceptions about digital-first health experiences. Virtual care is no longer a stopgap but an integral part of a seamless, anytime, anywhere health ecosystem. 🌍 We're witnessing the rise of B2B2C models in remote consultations, with companies like Teladoc Health and Amwell partnering with insurance providers to integrate their services into health plans. Public sector collaborations, like eConsult Health 's partnership with the NHS in the #UK, underscore the potential for remote consultations to enhance efficiency and accessibility at a national level. The digital health landscape is evolving rapidly, with advancements in remote consultations, mental health support, at-home diagnostics, and patient monitoring. AI and generative AI transform care delivery, making it more efficient, personalized, and patient-centric. 🤖 Yet, challenges remain. While venture capital funding for digital health has stabilized after the pandemic boom, it remains below its 2021 peak. Sectors like digital therapeutics face reimbursement hurdles, and we've seen major players like Walmart and Optum close telehealth businesses. Looking ahead, we anticipate further consolidation in digital health, driven by acquisitions to create broader ecosystems encompass telemedicine, mental health, and other specialized services. As healthcare leaders, we must leverage these digital advancements to improve access, enhance patient outcomes, and drive efficiency in our healthcare systems. The future of healthcare is digital, and the time to embrace this transformation is now. Congratulations to all the finalists! 🎉 Looking forward to the grand finale at #HLTH2024 in #LasVegas! 🙌 By the way, the pink drink that we were holding was delicious—and nonalcoholic! The Digital Health Hub Foundation - Digital Health Awards #HealthcareInnovation #DigitalHealth #UCSFHealthHub #Networking #HealthTech #Entrepreneurship #LasVegasFinale Walter Greenleaf, PhD Daniel Kraft, MD Unity Stoakes StartUp Health University of California, San Francisco UCSF Innovation Ventures American Association for Precision Medicine (AAPM) WISE World Investors & Entrepreneurs Society #AAPMhealth #aapm_health

94

7 Comments

Chris Garabedian, CEO, Xontogeny & Portfolio Manager, PXV Fund, Alyssa Abo, MD, MBA, & Suzy Engwall 🚀 Thrilled to catch up with Chris Garabedian, CEO of Xontogeny and Portfolio Manager of PxV Fund, alongside industry pros Alyssa Abo, MD, MBA, and Suzy Engwall, at the HLTH Conference! We dove into some powerful trends driving healthcare innovation and investment—here’s a taste of the conversation: 🌟 On the Hunt for Breakout Companies: Chris is laser-focused on identifying companies on the verge of breakout, paying close attention to their customer base and the real traction they’re making in the market. 🔥 A Wave of Mergers & Acquisitions: A recent conversation with a healthcare leader revealed a startling reality—50% of today’s startups might not be around next year. This climate is sparking a wave of matchmaking between startups and suitors, as companies look for strategic partners to ensure longevity and success. 🎯 Why Team Matters: When investing in early-stage companies, Chris is all about the people. His focus? Founders’ networks, their track records, and what sets their solutions apart in a competitive landscape. ⚡ The Rise of Consumer-Centric Healthcare: The consumerization of healthcare is sparking incredible growth and reshaping the market, but it’s still challenging to pick winners. Healthcare remains a complex arena where innovative technology is essential, but standard reimbursement models continue to be the backbone of long-term viability. Exciting times ahead as we witness the rapid disruption of healthcare. 📈💥 #HLTH2024 #healthcareinnovation #venturecapital #Xontogeny #healthcarestartups #ConsumerHealth #mergersandacquisitions #healthtech Planetary Health First Mars Next #planetaryhealthfirstmarsnext

24

A prospective $3.1 billion U.S. IPO in a market with very few listed early childhood education firms. This rare public listing highlights the growing global trend of scaling early childhood education companies, as private equity and large operators seek consolidation for operational efficiencies. With increased focus on education investments, this IPO could pave the way for more large-scale moves in the sector. #Education #EarlyYears #Earlychildhoodeducation #Childcare #Nurseries #Preschools #Edtech #K12Education #PrivateEquity #VentureCapital #ImpactInvesting https://lnkd.in/dTu3DyPS

4

Excited to share insights from our recent panel discussion on the latest trends in biotech and healthcare investments. We touched upon the following topics: 💡 Investment Trends in Biotech and Healthcare: Opportunities include continued innovation, and emerging technologies. 🧬 Advancements in Longevity and Regenerative Medicine: Breakthroughs in senescent cell clearance, stem cell rejuvenation, telomere biology, and the Klotho protein hold promise for extending healthspan and lifespan. 👵 Ethical Implications of Extending Human Lifespan: Equitable access, overpopulation, cultural impacts, generational conflict, and autonomy are key dilemmas. Inclusive governance and public dialogue are crucial for responsible navigation. 🤖 AI and Precision Medicine: AI is transforming personalized healthcare by integrating multi-omic data, enhancing biomarker discovery, predictive modeling, and clinical decision support, paving the way for more tailored and efficient treatments. ✂️ Gene Editing and CRISPR Technology: Ethical considerations include safety, access, human enhancement, and consent. Regulatory frameworks must evolve to ensure robust governance, public engagement, and global coordination. 🏥 Decentralized Clinical Trials and Remote Monitoring: DCTs increase patient access and retention, collect real-world data, and save costs, but face challenges in data quality, regulatory compliance, and technology infrastructure. Remote monitoring enhances patient engagement and data integrity. 📱 Health Tech and Wearable Devices: Wearables enable remote monitoring and personalized care but face barriers like data privacy, accuracy, user experience, integration, cost, and regulatory oversight. 🚀 Regulatory Pathways for Innovative Therapies: Biotech companies navigate complex, evolving frameworks. Solutions include developing clear guidelines, fostering regulatory flexibility, promoting global harmonization, and ensuring patient engagement. This discussion highlighted the incredible potential and intricate challenges in the biotech and healthcare sectors. Together, we can drive innovation while addressing ethical and regulatory concerns to improve global health outcomes. 🌟 #Biotech #HealthcareInnovation #LongevityResearch #PrecisionMedicine #GeneEditing #ClinicalTrials #HealthTech #AI #Wearables WISE World Investors & Entrepreneurs Society Private Investment Forum Worldwide American Association for Precision Medicine (AAPM) #RegulatoryAffairs #PublicHealth #AI #News

41

2 Comments

The latest #SVBHealthcare report found that VCs deployed $7.2 billion to healthcare-focused #AI companies last year. Read FierceHealthcare’s article about the report for an overview of what recent AI investment trends mean for the healthcare innovation space

52

Can't wait to reconnect with the brilliant Amanda Herson and join the discussion with Maciek Gnutek and Iain Martin at Slush about our fund models and what they mean for Founders ❄ 🚀

17

💡Benchmarks in the investment industry serve as a standard for measuring the performance of securities, mutual funds, or investment managers. They provide a reference point for analyzing allocation, risk, and return of a portfolio, enabling investors to make informed decisions. Thanks Peter Walker for keeping us all informed!! Can’t wait for this!! Follow and get on the waitlist for this one! #benchmarks #fundraising #Capitalraise #founders #womenshealth #femhealth #medtech #wellness

16

Had a blast diving into Amir Dan Rubin's extensive healthcare career on Vital Signs. Amir previously served as the CEO of One Medical and Stanford Health Care, was an EVP at United/Optum and is now the Founding Managing Partner at Healthier Capital. Our conversation spanned payer-provider integrations, lessons learned from leading One Medical, applications of generative AI, and more. Some highlights: ⚡Combining care models We talked a lot about the One Medical/Iora combination. Amir argues that just because two care delivery approaches may occupy the same physical location (e.g., a clinic), that doesn’t mean they necessarily need to conform to the same economic model. For instance, One Medical and Iora were able to combine effectively despite the former being a membership model and the latter being global capitation. Amir emphasizes that much of the overhead resources (e.g., front desk staff, phlebotomy) can be shared across models. ⚡How One Medical uses generative AI to improve efficiency One Medical allows members to message the care team, and then uses NLP to read the message, figure out its content, and triage it to the appropriate team member. Amir is excited about leveraging internal knowledge graphs to get around hallucinations. This approach can point to relevant internal data in helping compose responses, creating more trust and accuracy in the outputs. ⚡Behind the Amazon acquisition One Medical was interested in expanding its direct to consumer offering. However, they recognized that customer acquisition was costly, which is why partnering with Amazon Prime’s existing membership base made sense for them. Amir explains how at their core, both Amazon and One Medical are all about using technology and logistics to create an excellent customer experience. An awesome conversation ranging from health system innovation to startup strategy to health tech investing! Listen to our full episode below: Spotify: https://spoti.fi/3Wrbnol Apple: https://apple.co/3XWOomb

129

7 Comments

🚀 Biotech Booms Again: Arch Closes $3B+ to Ignite Innovation! 🚀 ARCH Venture Partners just closed a massive $3B+ fund, signaling a major comeback for biotech investments after a period of uncertainty. This new fund, Arch's 13th, is aimed at building and supporting early-stage biotech companies that are pushing the boundaries of healthcare innovation. 🧬 What makes this fund special? It's focused on transformational technologies that could revolutionize healthcare: ▶️ Programmable cell therapies with Arsenal Biosciences, Inc. 🧫 ▶️ Advanced treatments for inflammatory and fibrotic diseases with Mirador Therapeutics 💊 ▶️ AI-driven drug discovery from Xaira Therapeutics 🤖 ▶️ Next-gen GLP-1 receptor agonists from Metsera for fighting obesity 📊 According to #RobertNelsen, Arch’s co-founder, AI, and data-driven insights are set to reshape the future of biotech and healthcare. And ARCH Venture Partners is positioned to drive this transformation by fostering innovation at scale. 💬 “We remain incredibly excited by the pace of innovation and efforts to understand disease at a deeper level,” said #KeithCrandell, managing director at Arch. This move comes as biotech investment is beginning to rebound, as evidenced by other major players like Bain Capital Life Sciences Fund LP Sciences recently raising $3 billion as well. The sector is buzzing with optimism as more capital flows into #biopharma, #medicaldevices, #diagnostics, and #lifesciencestools, targeting unmet medical needs globally. 🌍 From early-stage startups to market-shaping discoveries, this fund will be pivotal in building the future of medicine. Is this the spark that will ignite the next biotech revolution? 🔥 🔗 Read the full story: https://lnkd.in/eX4pbexe #Biotech #VentureCapital #Innovation #Healthcare #AI #DrugDiscovery #MedTech #LifeSciences #Investment #Startups #CellTherapy #ArtificialIntelligence #HealthTech #VCFunding #Biopharma #Diagnostics #AIinHealthcare #Biotechnology

14

Our partner Eddie Eltoukhy has identified these opportunities in Biotech. Eddie has a PhD in bioengineering from Massachusetts Institute of Technology and over a decade experience as an operator. Reach out to him if you are working on these areas of biotech. Pear VC - Technology-Driven Therapeutic Platforms Companies developing therapeutic assets with a core product engine Proprietary tool, workflow, or samples leading to novel biological data sets Preference for omics platforms or high throughput screening / engineering workflows First-in-class or best-in-class drugs - Next-Generation Therapeutic Modalities Technologies to improve the efficacy, safety, access, or reach of next-gen modalities including the following: Genomic medicines (gene tx & gene editing) Cell therapies Targeted protein degraders Antibody-drug conjugates Radiopharma - Precision Medicine New technologies supporting the discovery of novel biomarkers and the generation of proprietary data sets for applications in: Disease screening Therapy selection Recurrence monitoring - Life Sciences + AI Software Platforms Software & AI-driven platforms to improve all aspects of life sciences R&D, including: Target discovery and validation Drug design and optimization Manufacturing Regulatory Clinical development

118

5 Comments

This article by the WSJ is critically important for public health officials and HealthTech entrepreneurs to internalize. We need multiple solutions for patients to move towards post GLP-1 usage. These solutions need to be easy to implement, non-disruptive to daily life and focused on caloric restriction , lifestyle change and muscle gain. Too many startups are still focused on GLP-1 prescription and delivery. Not enough people focused on the next stage of the weight management journey. As the Journal states, the benefits of the GLP-1 craze are only going to be successful long term if the transition off of them is successful. Otherwise, we risk unforeseen, long term consequences to a large group of patients stuck on GLP-1's with no healthy way to transition off. https://lnkd.in/dYBd3HaN Meghan FitzGerald James Stearns Dominic Perks John LaMattina Raju Kucherlapati

35

2 Comments

I’m a strong believer in the idea that leading is largely about building empathy. The job isn’t just helping others understand the mission - it’s helping them complete the mission and building alignment through personal context. To take it a step further, you can’t be empathetic if you aren’t curious. Curiosity drives us to ask deeper questions - those questions build empathy and, then, we become more aligned.

6

Harnessing Proprietary Information for Strategic Healthcare Investments Healthcare investments offer a unique combination of financial returns and the potential for significant social impact. For family offices and discerning investors, navigating this complex landscape requires more than just capital—it demands strategic insights fueled by proprietary information. The Foundation of Strategic Investment: Proprietary Information In the investment world, knowledge is power. This is particularly true in the healthcare sector, where regulatory landscapes, technological advancements, and policy changes can drastically impact the viability and potential of investment opportunities. Access to proprietary information gives investors a critical edge, enabling them to: - Anticipate Market Movements: With insights into healthcare policies and emerging trends, investors can position their portfolios to capitalize on upcoming shifts in the market. - Enhance Due Diligence: Tailored underwriting and due diligence tools grounded in exclusive data can highlight risks and reveal hidden potentials in investment prospects. - Maximize Value Creation: By understanding the intricacies of the US healthcare economy, investors can devise strategies for long-term value creation, rather than short-term gains. Empowering Family Offices Family offices often seek investments that offer both competitive financial returns and the opportunity to create a positive legacy. By refining investment platforms to address the specific needs of these entities, such as instant diversification and upside capture, they can achieve their financial and legacy-driven goals. These platforms can provide: - Market Insights: Curated intelligence that focuses on the most promising healthcare segments. - Educational Resources: In-depth content to deepen the understanding of healthcare technology trends and investment strategies. Building Relationships and Trust Investing is not just about the numbers; it's also about people. To attract and retain high-potential family office prospects, investment platforms must foster empathy and engagement. This involves: - Offering Exclusive Rights: Providing access to follow-on deals and direct investment opportunities with board or advisory roles. - Understanding Emotions: Addressing fears of missing out on prime opportunities due to geographical limitations and dissatisfaction with average investment options. - Creating Community: Facilitating a network of like-minded investors focused on collaborative, high-impact healthcare investments. Harnessing proprietary information is critical for making strategic healthcare investments that offer significant financial returns and contribute to the betterment of society. If you like to learn more about strategic healthcare investments or discuss your specific investment goals and how proprietary information can be leveraged to achieve them? Please feel free to reach out or leave a comment below.

20

1 Comment

At Today’s Cardiology Innovation Showcase, co-hosted by UCSF Innovation Ventures and the Department of Cardiology, several innovative projects and insights were presented. I have summarized the key insights that I found most impactful: Heart Failure: A growing concern 1. High prevalence: 6.7 million in the US; 60 million worldwide 2. Increasing incidence in the US, especially among older adults 3. Significant mortality rates and economic burden 4. Innovative solutions in development: -Advanced diagnostic sensors and therapeutic devices -Remote monitoring solutions (HeartLogic, Triage HF, cardioMeMs, Cordella) -AI-enabled medication optimization (Optima Heart) Valvular Heart Disease: An emerging challenge 1. High prevalence, expected to double by 2050 2. Severe consequences if untreated 3. Key research areas: -Early identification and prevention -Prediction of sudden/arrhythmic death -Personalized intervention strategies -Addressing treatment disparities Bridging academia and industry 1. Focus on bedside-identified unmet needs 2. Align academic research with industry capabilities 3. Bridge the knowledge gap between clinicians and industry experts From innovation to entrepreneurship 1. Distinguish between unrealized innovation and realizing/realized entrepreneurship 2. Emphasize early commercialization planning 3. Prioritize speed-to-market post-launch (Data shared by the guest speakers from department of cardiology, UCSF)

2

Check out this insightful panel discussion on precision therapeutics with our portfolio company Circular Genomics

7

A series for those interested in listening to transformational healthcare

3